Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Budget 2025: a missed opportunity for UK life sciences Despite bold rhetoric, today’s Budget delivered little of the certainty, investment or strategic direction the UK life sciences sector urgently needs
  2. HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception HitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on...
  3. Almac announces multi-million-pound investment in Singapore Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country
  4. Eli Lilly becomes first $1 trillion pharma company Fuelled by the GLP-1 boom, the drugmaker's stock has surged by more than 35% this year, with the company reaching a $1 trillion valuation on Friday — becoming the first...
  5. hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and...

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Finance Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Read more
Finance On 26 November, the Chancellor of the Exchequer, the Rt Hon Rachel Reeves MP, delivered the 2025 UK Autumn Budget

Response to Budget from the Institution of Chemical Engineers (IChemE)

Read more
Research & Development The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential...

Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research

Read more
Finance New tax breaks promise to fuel UK biotech scale-ups, but escalating workspace rates threaten to slow the momentum

UK bioindustry edges toward a critical turning point after the autumn budget

Read more
Finance Despite bold rhetoric, today’s Budget delivered little of the certainty, investment or strategic direction the UK life sciences sector urgently needs

Budget 2025: a missed opportunity for UK life sciences

Read more
Finance Fuelled by the GLP-1 boom, the drugmaker's stock has surged by more than 35% this year, with the company reaching a $1 trillion valuation on Friday — becoming the first...

Eli Lilly becomes first $1 trillion pharma company

Read more
Finance HitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on...

HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception

Read more
Finance Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country

Almac announces multi-million-pound investment in Singapore

Read more
Finance hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and...

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

Read more
Finance Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech...

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Read more
Finance Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC...

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Read more
Finance The acquisition brings promising clinical-stage obesity candidates into Pfizer's portfolio, giving the pharma company a leg up in one of the most dynamic and high-growth...

Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals

Read more
Finance CARBOGEN AMCIS today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG

CARBOGEN AMCIS secures refinancing to support growth and investment

Read more
Manufacturing CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

Read more
Finance Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Read more
Finance The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate...

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

Read more